Linking Postoperative Pain, GCF NLRP3 , and Treatment Success Following MTA Full Pulpotomy Vs Root Canal Treatment in Symptomatic Irreversible Pulpitis (NLRP3)
Linking Postoperative Pain, GCF NLRP-3 Dynamics, and Treatment Success Following MTA Full Pulpotomy Versus Root Canal Treatment in Symptomatic Irreversible Pulpitis : A Randomized Clinical Trial
To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Aim: To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.
Methods: This is a two-arm, parallel, assessor-blinded, randomized trial conducted at the Endodontic clinic, Faculty of Dentistry, Cairo University. Sixty patients with a periapical index score ≤ 2 will be randomized to receive either full pulpotomy with MTA or single-visit root canal treatment (n=30 per group). The primary outcome is postoperative pain at 24 hours on an 11-point Numerical Rating Scale. Secondary outcomes are:
pain at 6, 12, 48 and 72 hours and on day 7; number of ibuprofen 400 mg tablets taken over 7 days; GCF NLRP3 levels measured by ELISA preoperatively from tooth and healthy contralateral (internal control) and on day 7 from tooth; clinical and radiographic success at 6 and 12 months.
Analysis will follow the intention-to-treat principle, using the independent-samples t-test or Mann-Whitney U test, the chi-square or Fisher's exact test, and Spearman's rank correlation, with significance set at P ≤ 0.05.
Expected significance: The trial will show whether a simpler, pulp-preserving procedure offers pain and success outcomes comparable to root canal treatment, and whether GCF NLRP3 can serve as a chairside biomarker of healing.
Keywords: symptomatic irreversible pulpitis; full pulpotomy; mineral trioxide aggregate; root canal treatment; postoperative pain; NLRP3 inflammasome; gingival crevicular fluid
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Giza Governorate
-
Al Manyal, Giza Governorate, Ägypten
- Cairo University
-
Kontakt:
- Bassant yasser El-Saharty, assistant lecturer
- Telefonnummer: 01286858288
- E-Mail: bassantyasser@dentistry.cu.edu.eg
-
Kontakt:
- radwa sameeh emara, lecturer
- Telefonnummer: 01227141312
- E-Mail: radwa.emara@dentistry.cu.edu.eg
-
Unterermittler:
- lubna shafie, professor
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients 18-40 years old.
- Male or female
- Mandibular molars with SIP: preoperative sharp, moderate or severe pain, with normal periapical radiographic appearance or slight widening(PAI ≤ 2)
- Systemically healthy (ASA I) or controlled disease (ASA II)
- Able to understand NRS and sign informed consent
- Good oral hygiene, with no plaque or calculus, no bleeding on probing (BOP
Exclusion Criteria:
- Medically compromised patients with significant systemic disorders (ASA III or IV)
- History of intolerance to NSAIDs/ Use of ibuprofen in the last 12 hours
- Two or more adjacent teeth requiring endodontic treatment
- External or internal root resorption
- Vertical root fracture
- Periapical lesion
- Controlled diabetes & smoking
- Acute periapical abscess or acute exacerbation of a chronic abscess
- Pregnancy
- Long-term corticosteroid use
- Mobility grade II or III
- Previous root canal therapy
- Non-restorability
- TMJ problems, bruxism, clenching or traumatic occlusion
- Inability to perceive given instructions
- Antibiotic intake during the 10 days before treatment (may alter GCF inflammatory mediators)
- Gingival bleeding (gingivitis), recession > 3 mm or pocketing at the GCF sampling sites of the study or contralateral tooth
- Absent contralateral tooth, or one that is carious, deeply restored or endodontically treated (it is the GCF control)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Non-surgical root canal treatment
Canals explored with k-file #08 & #10 hand files; WL with EAL, confirmed radiographically. Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion. Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion. Shaping sequence
Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer. 6 Coronal seal & baseline film Same GIC base & bonded composite as pulpotomy group; immediate postoperativeradiograph |
After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl. Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded. Pulp capping & restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases. |
|
Experimental: full pulpotomy with MTA
After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl. 2 Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded. 3 Pulp capping & restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit. ! If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases. |
Canals explored with k-file #08 & #10 hand files; WL with EAL, confirmed radiographically. 2 Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion. 3 Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion. 4 Shaping sequence
Coronal seal & baseline film Same GIC base & bonded composite as pulpotomy group; immediate postoperativeradiograph
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
postoperative pain after 24 hours
Zeitfenster: 24 hours
|
using 11-point numeric rating scale (NRS) to score postoperative pain after 24 where 0 means no pain and 10 is worst imaginable pain |
24 hours
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
postoperative pain after 6,12,48,72 and 7 days
Zeitfenster: 6, 12, 48,72 hours and 7 days
|
using 11-point numeric rating scale (NRS) to score postoperative pain after 6, 12, 48,72 hours and 7 days where 0 means no pain and 10 is worst imaginable pain. |
6, 12, 48,72 hours and 7 days
|
|
GCF levels of NLRP3
Zeitfenster: preoperative and 7 days postoperative
|
using ELISA to detect levels of NLRP3 from gingival crevicular fluid |
preoperative and 7 days postoperative
|
|
Clinical and radiographic success
Zeitfenster: 6 months
|
Evaluating clinical success ( absence of pain, swelling , sinus tract/ fistula, and tooth is functional) and radiographic success ( absence of periapical radiolucency, internal/ external resorption) |
6 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- New ENDO 3.3.3-New ENDO 7.1.2
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .